Join us in-person in San Diego for the Antibody Engineering & Therapeutics conference where Just-Evotec Biologics will be presenting. We look forward to speaking with you at booth no. 111!
- Randal Ketchem, SVP Discovery and Molecular Design at Just-Evotec Biologics
- Jon Gunther, VP Business Development at Just-Evotec Biologics
Scientific Breakfast Session | 7 December at 7:30am PT in San Diego Ballroom C
AI-Derived Antibody Discovery – Humanoid Fab and VHH Biotherapeutics for Global Good
Ideally, antibody therapeutics are both efficacious and developable. Antibody discovery platforms tend to focus on either in vivo immunizations or libraries of randomized CDRs on germline frameworks. While immunizations lead to high affinity and specificity, B-cells have no selective pressure to produce developable antibodies. Standard libraries generally do not represent actual human response. We have developed an AI-generated antibody library platform utilizing a Generative Adversarial Network (GAN) which generates novel Fab and humanized VHH sequences that mimic natural human response as well as biasing toward diversity, desired efficacy, and developability features. The resulting libraries have been shown to be successful in obtaining active antibodies.
Presented by Randal Ketchem, SVP Discovery and Molecular Design at Just-Evotec Biologics
Randal KetchemSVP Discovery and Molecular Design
Randy received his PhD in Molecular Biophysics from Florida State University, focusing on experimental protein structure determination, resulting in the first membrane-bound protein structure solved by Solid State NMR. As part of this effort he developed computational methods for the structure calculation and refinement of membrane-bound proteins. Randy continued his training in structural biology in a postdoctoral fellowship at The Scripps Research Institute where he expanded his experimental and computational efforts into solution-based protein structure. Randy then joined Immunex in 1997 to apply his expertise in protein structure modelling and analysis to efforts in the development of biologic-based therapeutics. During his many years of experience at Immunex, Amgen, and Just Biotherapeutics he has led efforts to engineer protein therapeutics, invented novel therapeutic modalities and computational methods for therapeutic design, and developed computational and experimental approaches to understanding and controlling biophysical properties of biological macromolecules. Randy has made significant contributions in antibody design, epitope mapping, molecular assessment, stability engineering, construct design, protein structure analysis, and protein engineering. At Just – Evotec Biologics, Randy leads the Molecular Design team, integrating biologics discovery and molecular design strategies into the entire therapeutic pipeline.